how to preparer autologous anti-tumor vaccine ?
Professor Laura MARCONATO's team at the University of Bologna has shared with us their experience in preparing treatment for canine lymphoma.
Active immunotherapy in dogs with B-cell Lymphoma : A 5-year experience in two oncolgy centers
Proven survival benefit of adding APAVAC active immunotherapy to chemotherapy in dogs with B-cell lymphoma
La gazette du midi - December 2022
Hastim inaugurates its new research centre in Toulouse to develop personalised immunostimulant treatments for cancer
Multimodal management, including immunotherapy, form multicentric squamous cell carcinoma
In the context of the need for rapid management of multicentric squamous cell carcinoma, which is uncommon in horses, the autologous immunostimulant treatment APAVAC takes its place among the therapeutic modalities for a difficult-to-treat condition.
The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications
Bone cell transfection in tissue culture using hydroxyapatite microparticles
Calcium phosphate ceramics (especially hydroxyapatite) are able of transfecting cells grown in tissue culture with high efficiency and effectiveness, which also extends to cells that are not in direct contact with the particles.
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers
Possible sous titre dolor sit amet, consectetur adipiscing elit. Cras sed purus commodo dui accumsan pharetra a ullamcorper turpis. Maecenas facilisis enim risus.
Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma
In combination with a chemotherapy regimen (l-asparaginase, vincristine, cyclophosphamide, doxorubicin, lomustine and prednisone), APAVAC immunotherapy significantly prolongs the time to progression (TTP) of dogs with advanced indolent lymphoma.
A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients
An approach to produce an autologous therapeutic antitumor vaccine using hydroxyapatite (HA) for vaccinating cancer patients.